Therefore, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been recommended clinically as first-line therapies in CKD patients (Chen et al., 2019a). Here, ACE is linked to chronic kidney disease.